Immunogenic characteristics of <i>Avibacterium paragallinаrum</i> (serogroup B) isolates and strains by M. S. Firsova, V. A. Yevgrafova, A. V. Potekhin, R. V. Yashin, O. V. Pruntova, V. S. Russaleyev

Subjects: Get full text

COVID-19 clinical presentation, management, and epidemiology: a concise compendium by David P. Maison, David P. Maison, Hawi Tasissa, Amelia Deitchman, Michael J. Peluso, Youping Deng, F. DeWolfe Miller, Timothy J. Henrich, Mariana Gerschenson

Subjects: Get full text

Disparities in the uptake of HPV-related cancer prevention strategies among women by HIV status in Puerto Rico by Marievelisse Soto-Salgado, Melisa Ramos-Sepúlveda, Jeslie M. Ramos-Cartagena, Maribel Tirado-Gómez, Humberto M. Guiot, Cristina Muñoz-Masso, Lorena González-Sepúlveda, Ana Patricia Ortiz

Subjects: Get full text

Porcine reproductoryand respiratory syndrome in the Russian Federation: control systems, risk identification by A. S. Oganesyan, M. A. Shibayev, N. E. Baskakova

Subjects: Get full text

Epizootogical aspects of avian influenza prevention and control strategy in modern Russia by M. S. Volkov, V. N. Irza, A. V. Varkentin, A. S. Starova

Subjects: Get full text

A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges by Lesley C. Dupuy, Michelle J. Richards, Brian D. Livingston, Drew Hannaman, Connie S. Schmaljohn

“…Here, we performed a comparative evaluation of the immunogenicity and protective efficacy of individual optimized VEEV, WEEV, and EEEV DNA vaccines with that of a 1 : 1 : 1 mixture of these vaccines, which we have termed the 3-EEV DNA vaccine, when delivered by IM EP. …”
Get full text

Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial by Ernest Choy, Kerenza Hood, Emma Thomas-Jones, Eleanor Barnes, Keith Wilson, Christian H Ottensmeier, Debbie Harris, Adrian Hill, Mark Tuthill, Richard Adams, Catherine Porter, Katie Ewer, Sian Griffin, Rebecca Tangney, Joanne Euden, Shirley Pringle, Lawrence Raisanen, Ruby Ray, Lisette Sheena Nixon, Melanie Varley, Craig Bodman, Paola Cicconi, Vivien Dagley, Steven Knapper

“…Participants will be administered AZD7442 on day 0 followed by a SARS-CoV-2 vaccination 28 days later. Participants will be randomised (1:1) to the Moderna vaccine or Pfizer/BioNTech vaccine. …”
Get full text

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial by Junya Furukawa, Yasumasa Kakei, Sae Murakami, Hiroshi Kita, Hideto Ueki, Takuto Hara, Jun Teishima, Nobuyuki Hinata, Hideaki Miyake, Masato Fujisawa, Toshiro Shirakawa

“…Abstract Background This is a multicenter, open-label, single-arm clinical trial to evaluate the safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer. …”
Get full text

The Role of Dendritic Cells in Adaptive Immune Response Induced by OVA/PDDA Nanoparticles by Daniele R. Pereira, Yunys Pérez-Betancourt, Bianca C. L. F. Távora, Geraldo S. Magalhães, Ana Maria Carmona-Ribeiro, Eliana L. Faquim-Mauro

Subjects: Get full text

Unmasking the Neglected Cholera Outbreaks in Sub-Saharan Africa by Beenzu Siamalube, Emmanuel Ehinmitan

Subjects: Get full text

RNA diagnostics and therapeutics: a comprehensive review by Adeela Fathima Saju, Aditi Mukundan, Divyashree MS, Raghu Chandrashekhar, Archana Mahadev Rao

Subjects: Get full text

NERVE 2.0: boosting the new enhanced reverse vaccinology environment via artificial intelligence and a user-friendly web interface by Andrea Conte, Nicola Gulmini, Francesco Costa, Matteo Cartura, Felix Bröhl, Francesco Patanè, Francesco Filippini

Subjects: Get full text

Foreword: Prevention of COVID-19, Influenza, and Respiratory Syncytial Virus in At-Risk Populations by Stefan Gravenstein

Subjects: Get full text

The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study by Yin Yin, Min Jia, Yufeng Li, Wei Zhao, Shuhong Chen, Peiyuan Huo, Qinghua Zhao, Lan Yu, Cha Wang, Yirui Ma, Meixia Wang, Jing Zhang

“…This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone. Method: This randomized, double-blind, parallel-controlled Phase Ib clinical study was conducted in healthy Chinese population to evaluate the safety, pharmacokinetics, and neutralizing activity of rhRIG at dosages of 20IU/kg and 40IU/kg in combination with vaccines, and to compare the neutralizing activity of rhRIG + vaccine with that of HRIG + vaccine and vaccine alone. 72 healthy participants divided into 6 groups of 12 individuals. …”
Get full text

Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers – the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study protocol by Nick Andrews, Mary Ramsay, Maria Zambon, Victoria Hall, Sarah Wallace, Susan Hopkins, Jean Timeyin, Tim J G Brooks, Amoolya Vusirikala, Meera Chand, Andre Charlett, Sakib Rokadiya, Colin S Brown, Madhumita Shrotri, Peter D Kirwan, Michele Cole, Natalie Gillson, Ana Atti, Sarah Foulkes, Andrew Taylor-Kerr, Blanche Oguti, Jasmin Islam

“…Individuals complete enrolment and fortnightly questionnaires on exposures, symptoms and vaccination. Follow-up is 12 months from study entry, with an option to extend follow-up to 24 months.The primary outcome of interest is infection with SARS-CoV-2 after previous SARS-CoV-2 infection or COVID-19 vaccination during the study period. …”
Get full text

The development and maintenance of immunity against visceral leishmaniasis by Rahul Tiwari, Awnish Kumar, Vishal Kumar Singh, Rajneesh, Shashi Bhushan Chauhan, Shyam Sundar, Susanne Nylén, Christian Engwerda, Rajiv Kumar

Subjects: Get full text

CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution by Chuang Li, Jie Yu, Rahma Issa, Lili Wang, Mingzhe Ning, Shengxia Yin, Jie Li, Chao Wu, Yuxin Chen

Subjects: Get full text

Immune status improvement in piglets through the use of interferon-containing products during specific prevention of porcine pleuropneumonia by A. G. Shakhov, L. Yu. Sashnina, V. A. Prokulevich, Yu. Yu. Vladimirova, M. I. Adodina

Subjects: Get full text

Assessing the use of geospatial data for immunization program implementation and associated effects on coverage and equity in the Democratic Republic of Congo by Dosithée Ngo-Bebe, Patricia Mechael, Fulbert Nappa Kwilu, Théophane Kekemb Bukele, Félicité Langwana, Genèse Lolimo Lobukulu, Marcelo Ilunga Kalonji, Bahindwa Kalalizi, Kevin Tschirhart, Christophe Lungayo Luhata, Carine Gachen

Subjects: Get full text

Covid-19 Aşı Karşıtlığı Tutumunda Çok Yüksek Etkileşime Sahip Trollerin Ortak Özelliklerini Belirlemeye İlişkin Bir Araştırma by Huseyn Aghayev, Ulkar Gulmammadzada, Çiğdem Aytekin

Subjects: Get full text